GlassScriptPhysician profile
Bruce A Jacobson
NPI 1558314971
$6,852.86
in general payments reported to CMS, 2019-2025
27 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,509 · 2020: $167 · 2021: $272 · 2022: $976 · 2023: $1,169 · 2024: $1,051 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,927.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,734.54 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $644.45 | 2022-2025 | |
| Glaxosmithkline, LLC. | $522.43 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $464.43 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.29 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $441.10 | 2019-2025 | |
| Amgen INC. | $401.09 | 2023-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $384.42 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $276.58 | 2019-2022 | |
| Exact Sciences Corporation | $233.41 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $187.19 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $159.27 | 2019-2023 | |
| Medtronic Vascular, INC. | $137.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.76 | 2019-2022 | |
| Pfizer INC. | $108.10 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $102.69 | 2021-2025 | Loreev Xr |
| Novo Nordisk INC | $97.96 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.70 | 2019-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $77.70 | 2022 | |
| Eisai INC. | $44.52 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $34.89 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $27.16 | 2024 | Rexulti |
| Radius Health, INC. | $24.74 | 2024 | Tymlos |
| Abbott Laboratories | $23.56 | 2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $21.26 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.76 | 2024 | Rytary |
| E.R. Squibb & Sons, L.L.C. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.